TrialThe Lancet. Oncology2023

First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial.

Samuel L Cytryn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.